Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Sarcoidosis

In brief

The purpose of this proof of concept study was to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.

Key facts

Study ID

NCT04064242

Run by

Novartis Pharmaceuticals

People needed

62

Starts

2020-09-23

Expected to finish

2023-12-12

Last updated by the study team

2025-04-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have a body mass index (BMI) at screening within the range of 18 - 46 kg/m2. BMI = Body weight (kg) / [Height (m)]2
• Biopsy proven pulmonary sarcoidosis diagnosed > 1 year prior to screening
• Scadding stage II, III or IV as determined by the most recent chest x-ray obtained within 12 months prior to screening or at screening (confirmed by the Investigator)
• HRCT extent of fibrosis <20% (confirmed by the central imaging reader) at screening
• Treatment with 5-15 mg/day prednisone (or prednisone oral equivalents) for ≥ 6 months prior to screening.
• Co-medication with methotrexate or azathioprine for ≥ 6 months prior to screening (Note: hydroxychloroquine is allowed as background therapy but not required)
• Able to perform reliable, reproducible pulmonary function test maneuvers per American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines

You may not qualify if…

• Diagnosis of significant pulmonary hypertension (WHO group 5) requiring pharmacological treatment
• Active cardiac sarcoidosis requiring treatment. Inactive cardiac sarcoidosis or stable cardiac sarcoidosis not requiring treatment are permissible.
• A known diagnosis of neurosarcoidosis
• Forced vital capacity (FVC) <50% of predicted at screening (central read)
• Modified British Medical Research Council (mMRC) dyspnea scale ≥ 3 at screening
• Concomitant treatment with leflunomide, cyclophosphamide, mycophenolate, infliximab, etanercept, adalimumab, golimumab, ustekinumab, roflumilast, pentoxifylline, and abatacept within 12 weeks of screening
• Prior treatment with rituximab, canakinumab, anakinra, and tocilizumab
• Current use of any inhaled substance, including but not limited to tobacco, marijuana products and use of electronic cigarette or vaping device, and excluding inhalers or nebulizers prescribed for pulmonary sarcoidosis
• Any conditions or significant medical problems which in the opinion of the investigator and in consultation with the sponsor, immunocompromises the patient and/or places the patient at unacceptable risk for immunomodulatory therapy
• Contraindication to FDG-PET scan investigations such as severe claustrophobia or uncontrolled diabetes
• History or current diagnosis of ECG abnormalities not due to Cardiac Sarcoidosis and indicating significant risk of safety for patients participating in the study
• A diagnosis of Lofgren's syndrome
• A history of pancreatitis

Where it is running

• Novartis Investigative Site — Birmingham, Alabama, United States
• Univ of Florida College of Medicine x — Gainesville, Florida, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• John Hopkins Asthma And Alrgy Cntr — Baltimore, Maryland, United States
• Icahn School Of Med At Mount Sinai . — New York, New York, United States
• East Carolina University . — Greenville, North Carolina, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• Novartis Investigative Site — Brno, Czechia
• Novartis Investigative Site — Olomouc, Czechia
• Novartis Investigative Site — Aarhus N, Denmark
• Novartis Investigative Site — Hellerup, Denmark
• Novartis Investigative Site — Odense C, Denmark
• Novartis Investigative Site — Heidelberg, Baden-Wurttemberg, Germany
• Novartis Investigative Site — Essen, Germany
• Novartis Investigative Site — Frankfurt, Germany
• Novartis Investigative Site — Hamburg, Germany
• Novartis Investigative Site — Hanover, Germany
• Novartis Investigative Site — Bialystok, Poland
• Novartis Investigative Site — Lodz, Poland
• Novartis Investigative Site — Warsaw, Poland
• Novartis Investigative Site — Edinburgh, United Kingdom
• Novartis Investigative Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.